Press Releases
Connect Biopharmaceuticals Received Award of Jiangsu Science and Technology Support Program

(Taicang, Jiangsu, China, June 10, 2014)

Suzhou Connect Biopharmaceuticals announced today that the company has been awarded the “Science and Technology Support Program” from the Science and Technology Agency of Jiangsu Province, China.  

The Science and Technology Support Program  of Jiangsu Province recognizes and provides funding support for programs with significant technological breakthroughs and strong intellectual property rights. The goal of the Program is to encourage organizations to engage in forward-looking, innovative technology development, and to improve technical capabilities in research and development.


Media Contact:


About Suzhou Connect Biopharmaceuticals, Ltd.

Connect is a startup biopharmaceutical company dedicated to the discovery and development of novel therapeutics targeting G-protein coupled receptors (GPCR) for the treatment of autoimmune diseases, allergy and cancer. The company was founded by Dr. Zheng Wei, formerly Director of Immunology at Arena Pharmaceuticals, Inc., and Dr. William (Wubin) Pan, co-founder and formerly China President and Chief Operation Officer of Crown Biosciences, Inc., with investment from Xiang Tang Group. In addition to developing drug candidates through in-licensing, the company uses its proprietary GMab technology to discover and develop therapeutic antibodies against GPCR drug targets.

TEL/FAX: 0512-53577866


ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd. 苏ICP备17002143号

Technical support: Epower